Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ACP 01

Drug Profile

ACP 01

Alternative Names: ACP-01; Angiogenic Cell Precursors - Hemostemix; Endothelial progenitor cells - Hemostemix; VesCell

Latest Information Update: 24 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TheraVitae
  • Developer Hemostemix; Mahidol University; TheraVitae
  • Class Anti-inflammatories; Anti-ischaemics; Heart failure therapies; Ischaemic heart disorder therapies; Stem cell therapies; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inducing agents; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Peripheral arterial disorders; Thromboangiitis obliterans
  • No development reported Angina pectoris; Cardiomyopathies; Heart failure

Most Recent Events

  • 21 Oct 2019 Adverse events data from a phase II trial in Peripheral arterial disorders released by Hemostemix
  • 11 Jul 2019 ACP 01 is available for licensing as of 11 Jul 2019. http://hemostemix.com/
  • 04 Feb 2019 Hemostemix applies for Orphan Drug status in Peripheral arterial disorders (Critical limb ischaemia) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top